Gilead Sciences has expanded its collaboration with Tempus AI to gain broader access to the precision medicine company's real-world data resources and AI platform, according to GenomeWeb. The partnership gives Gilead access to Tempus's clinical database and AI-driven analytics capabilities.
Investing.com described the arrangement as an expansion of an existing collaboration between the two companies. Benzinga reported the partnership expansion, characterizing it as supporting Gilead's oncology pipeline. Financial terms were not disclosed.
For Tempus (NASDAQ: TEM), the deal reinforces a business model that increasingly relies on pharma data licensing alongside its diagnostics business. The company, which went public in 2024, has positioned pharma partnerships as a high-margin revenue stream complementing its per-test diagnostic reimbursement.
The timing coincides with multiple FDA regulatory actions for Tempus sequencing-based products. On the same day as the Gilead announcement, FDA filings show a PMA original application and PMA supplement for Tempus's xT CDx assay, plus a 510(k) substantial equivalence determination for its xR IVD product.
Tempus competes with Flatiron Health (owned by Roche), Guardant Health, and Foundation Medicine in offering real-world oncology data and companion diagnostics to pharma clients. The company's differentiation centers on the scale and multimodality of its dataset, combining sequencing, AI, and clinical data under one platform.